Monoclonal antibodies against human factor VIII molecular neutralize antihemophilic factor and ristocetin cofactor activities.
A series of monoclonal antibodies have been raised against a preparation of the factor VIII/von Willebrand factor molecule. Of the seven hybridomas showing specific activity against the factor VIII molecule in a solid-phase radioimmunoassay, three (F4.55, F4.77, and F4.264) have been shown to partially inhibit ristocetin-induced platelet aggregation and two (F4.115 and F4.415) inhibit the antihemophilic activity of the factor VIII molecule. An additional monoclonal antibody was directed against a contaminant of the factor VIII preparation and is an antifibrinogen antibody.
D000818:Animals; D000911:Antibodies, Monoclonal; D002460:Cell Line; D005169:Factor VIII / Q000276:immunology*; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D010954:Plasmacytoma; D011863:Radioimmunoassay; D012310:Ristocetin / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D014841:von Willebrand Factor / Q000276:immunology
D000911:Antibodies, Monoclonal; D014841:von Willebrand Factor; D012310:Ristocetin; D005169:Factor VIII